Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
Protagenic Therapeutics announced a private placement providing $1.5 million in upfront gross proceeds, with up to $3.5 million more available if two series of milestone-linked warrants are exercised in full, for total potential gross proceeds of up to $5 million. Proceeds will fund IND-enabling activities for PT00114 and initiate a planned Phase 1/2a trial in Generalized Anxiety Disorder, with first patient dosing targeted for Q2 2027. FDA pre-IND feedback identified no deficiencies that would preclude an IND submission.
Key figures
- Deal Value Usd
- 5000000
- Shares Offered
- 0
- Topline safety data
- H2 2027
- Upfront gross proceeds
- $1.5 million
- Exploratory efficacy data
- H1 2028
- First patient dosing target
- Q2 2027
- Total potential gross proceeds
- $5 million
- Milestone warrant potential proceeds
- $3.5 million
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.